This open-label, multicenter, treatment response guided study will evaluate the sustained
virological response and safety of the triple combination therapy boceprevir, Pegasys
(peginterferon alfa-2a) and Copegus (Ribavirin) in previously untreated patients with
genotype 1 chronic hepatitis C. In the lead-in phase, patients will receive a dual
combination therapy of Pegasys and Copegus for 4 weeks. In the following triple combination
therapy phase, 800 mg boceprevir, 180 mcg Pegasys and 1000-1200 mg Copegus will be
administered for 24, 32 or 44 weeks; the duration depending on the patient's treatment
response. The anticipated time on study treatment is up to 48 weeks.